Glenn P. Muir
Glenn P. Muir's purchase track record
How the stock did after each of Glenn P. Muir's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/5/2024 | STIM | $20K | +52.0% | +533.5% | +4.3% |
| 8/28/2024 | STIM | $21K | +9.7% | +427.3% | +6.5% |
| 8/14/2024 | STIM | $44K | -26.5% | +378.9% | +10.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
STIM shifts focus from devices to psychedelic infrastructure. Neuronetics announced it is moving away from solely manufacturing its TMS device and is building a platform to support psychedelic therapies. The change aims to broaden the company's role in the emerging mental-health market. The stock is currently trading near its $1.19 support level and has an RSI of 25.4, indicating a low momentum environment.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Repligen Completes BioLife Solutions Acquisition. Repligen has finalized its acquisition of BioLife Solutions, a move that follows shareholder approval of the merger. This transaction expands Repligen's portfolio in the biopharmaceutical sector. The stock recently reached a 52-week high, reflecting market interest in the company's growth strategy.
Transaction History
| CTKB | ▲ Buy | Option Exercise | 3,086 | — | 8/18/2026 | View on chart |
| STIM | ▲ Buy | Grant | 30,000 | $0 | 5/28/2026 | View on chart |
| RGEN | ▲ Buy | Grant | 995 | $0 | 5/14/2026 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 2,434 | $94K | 5/7/2026 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 3,366 | $88K | 12/16/2025 | View on chart |
| STIM | ▲ Buy | Grant | 7,554 | $0 | 10/20/2025 | View on chart |
| STIM | ▲ Buy | Grant | 30,000 | — | 5/22/2025 | View on chart |
| RGEN | ▲ Buy | Grant | 973 | $0 | 5/15/2025 | View on chart |
| STIM | ▼ Sell | Other | 44,444 | $100K | 2/7/2025 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 19,000 | $690K | 11/19/2024 | View on chart |
| STIM | ▲ Buy | Open Market | 25,000 | $20K | 9/5/2024 | View on chart |
| STIM | ▲ Buy | Open Market | 12,224 | $10K | 8/29/2024 | View on chart |
| STIM | ▲ Buy | Open Market | 12,776 | $11K | 8/28/2024 | View on chart |
| STIM | ▲ Buy | Open Market | 25,000 | $25K | 8/20/2024 | View on chart |
| STIM | ▲ Buy | Open Market | 25,171 | $19K | 8/14/2024 | View on chart |
| RGEN | ▲ Buy | Option Exercise | 5,000 | $181K | 8/1/2024 | View on chart |
| STIM | ▲ Buy | Grant | 25,000 | — | 5/30/2024 | View on chart |
| RGEN | ▲ Buy | Grant | 701 | $0 | 5/16/2024 | View on chart |
| STIM | ▲ Buy | Grant | 36,364 | — | 5/25/2023 | View on chart |
| RGEN | ▲ Buy | Grant | 686 | $0 | 5/18/2023 | View on chart |
| RGEN | ▲ Buy | Grant | 534 | $0 | 5/26/2022 | View on chart |
| STIM | ▲ Buy | Grant | 38,910 | — | 5/26/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Cytek spotlights spectral flow cytometry at ESCCA and ICCS conferences
Cytek Biosciences drew attention to the growing use of its spectral flow cytometry technology in clinical research at the ESCCA and ICCS conferences. The company also confirmed it will attend upcoming investor conferences. These are routine participation and awareness events rather than material business updates, with no new financial figures or product announcements disclosed. The current price sits within the stock's 52-week range of $3.28 to $6.18, below the average analyst target of $5.56.
Cytek spotlights spectral flow cytometry at ESCCA and ICCS conferences. Cytek Biosciences drew attention to the growing use of its spectral flow cytometry technology in clinical research at the ESCCA and ICCS conferences. The company also confirmed it will attend upcoming investor conferences. These are routine participation and awareness events rather than material business updates, with no new financial figures or product announcements disclosed. The current price sits within the stock's 52-week range of $3.28 to $6.18, below the average analyst target of $5.56.